Bovine Colostrum: Food Supplement

Author(s):  
Nikita Shevkar ◽  
Ramesh Gadekar ◽  
Swati Talele ◽  
Anil Jadhav
2001 ◽  
Vol 100 (6) ◽  
pp. 627 ◽  
Author(s):  
Raymond J. PLAYFORD ◽  
Christopher E. MACDONALD ◽  
Denis P. CALNAN ◽  
David N. FLOYD ◽  
Theo PODAS ◽  
...  

Gut ◽  
1999 ◽  
Vol 44 (5) ◽  
pp. 653-658 ◽  
Author(s):  
R J Playford ◽  
D N Floyd ◽  
C E Macdonald ◽  
D P Calnan ◽  
R O Adenekan ◽  
...  

BACKGROUNDNon-steroidal anti-inflammatory drugs (NSAIDs) are effective for arthritis but cause gastrointestinal injury. Bovine colostrum is a rich source of growth factors and is marketed as a health food supplement.AIMSTo examine whether spray dried, defatted colostrum or milk preparations could reduce gastrointestinal injury caused by indomethacin.METHODSEffects of test solutions, administered orally, were examined using an indomethacin restraint rat model of gastric damage and an indomethacin mouse model of small intestinal injury. Effects on migration of the human colonic carcinoma cell line HT-29 and rat small intestinal cell line RIE-1 were assessed using a wounded monolayer assay system (used as an in vitro model of wound repair) and effects on proliferation determined using [3H]thymidine incorporation.RESULTSPretreatment with 0.5 or 1 ml colostral preparation reduced gastric injury by 30% and 60% respectively in rats. A milk preparation was much less efficacious. Recombinant transforming growth factor β added at a dose similar to that found in the colostrum preparation (12.5 ng/rat), reduced injury by about 60%. Addition of colostrum to drinking water (10% vol/vol) prevented villus shortening in the mouse model of small intestinal injury. Addition of milk preparation was ineffective. Colostrum increased proliferation and cell migration of RIE-1 and HT-29 cells. These effects were mainly due to constituents of the colostrum with molecular weights greater than 30 kDa.CONCLUSIONSBovine colostrum could provide a novel, inexpensive approach for the prevention and treatment of the injurious effects of NSAIDs on the gut and may also be of value for the treatment of other ulcerative conditions of the bowel.


2001 ◽  
Vol 100 (6) ◽  
pp. 627-633 ◽  
Author(s):  
Raymond J. PLAYFORD ◽  
Christopher E. MACDONALD ◽  
Denis P. CALNAN ◽  
David N. FLOYD ◽  
Theo PODAS ◽  
...  

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective analgesics but cause gastrointestinal injury. Present prophylactic measures are suboptimal and novel therapies are required. Bovine colostrum is a cheap, readily available source of growth factors, which reduces gastrointestinal injury in rats and mice. We therefore examined whether spray-dried, defatted colostrum could reduce the rise in gut permeability (a non-invasive marker of intestinal injury) caused by NSAIDs in volunteers and patients taking NSAIDs for clinical reasons. Healthy male volunteers (n = 7) participated in a randomized crossover trial comparing changes in gut permeability (lactulose/rhamnose ratios) before and after 5 days of 50 mg of indomethacin three times daily (tds) per oral with colostrum (125 ml, tds) or whey protein (control) co-administration. A second study examined the effect of colostral and control solutions (125 ml, tds for 7 days) on gut permeability in patients (n = 15) taking a substantial, regular dose of an NSAID for clinical reasons. For both studies, there was a 2 week washout period between treatment arms. In volunteers, indomethacin caused a 3-fold increase in gut permeability in the control arm (lactulose/rhamnose ratio 0.36±0.07 prior to indomethacin and 1.17±0.25 on day 5, P < 0.01), whereas no significant increase in permeability was seen when colostrum was co-administered. In patients taking long-term NSAID treatment, initial permeability ratios were low (0.13±0.02), despite continuing on the drug, and permeability was not influenced by co-administration of test solutions. These studies provide preliminary evidence that bovine colostrum, which is already currently available as an over-the-counter preparation, may provide a novel approach to the prevention of NSAID-induced gastrointestinal damage in humans.


2001 ◽  
Vol 120 (5) ◽  
pp. A673-A674
Author(s):  
D MACK ◽  
M LARSON ◽  
S WEI ◽  
A WEBER ◽  
T MCDONALD

2012 ◽  
Vol 50 (05) ◽  
Author(s):  
A Blázovics ◽  
Á Szilvás ◽  
D Kleiner ◽  
L Kursinszki

Sign in / Sign up

Export Citation Format

Share Document